Development and In Vitro and In Vivo Evaluation of an Antineoplastic Copper(II) Compound (Casiopeina III-ia) Loaded in Nonionic Vesicles Using Quality by Design

Zenayda Aguilar-Jiménez, Mauricio González-Ballesteros, Silvia G. Dávila-Manzanilla, Adrián Espinoza-Guillén and Lena Ruiz-Azuara

Departamento de Química Inorgánica y Nuclear, Facultad de Química, Universidad Nacional Autónoma de México, Av. Universidad 3000, Mexico City DF 04510, Mexico
* Correspondence: lenar701@gmail.com

Abstract: In recent decades, the interest in metallodrugs as therapeutic agents has increased. Casiopeinas are copper-based compounds that have been evaluated in several tumor cell lines. Currently, casiopeina III-ia (CasIII-ia) is being evaluated in phase I clinical trials. The aim of the present work is to develop a niosome formulation containing CasIII-ia for intravenous administration through a quality-by-design (QbD) approach. Risk analysis was performed to identify the factors that may have an impact on CasIII-ia encapsulation. The developed nanoformulation optimized from the experimental design was characterized by spectroscopy, thermal analysis, and electronic microscopy. In vitro drug release showed a burst effect followed by a diffusion-dependent process. The niosomes showed physical stability for at least three months at 37 °C and 75% relative humidity. The in vitro test showed activity of the encapsulated CasIII-ia on a metastatic breast cancer cell line and the in vivo test of nanoencapsulated CasIII-ia maintained the activity of the free compound, but showed a diminished toxicity. Therefore, the optimal conditions obtained by QbD may improve the scaling-up process.

Keywords: nanocarriers; quality by design; niosome; cancer; Casiopeina III-ia; copper

1. Introduction

The use of metal drugs for the treatment of cancer has been of great interest in recent years. Even though platinum-based compounds are widely used for chemotherapy, there is still a low interest in the clinical use of metal-based drugs. This is attributed to their inherent toxicity. In this respect, the use of nanomedicine can be an alternative to reduce their toxic effects. Peña et al., reported that from the total number of articles published involving “nano”/“chemotherapy”/“metals”, 40% corresponded to essential metals, including copper which accounted for 10% of the search [1]. For example, cisplatin is one of the most used compounds for the treatment of several types of cancer. Nevertheless, the adverse effects have led to a search for diverse alternatives, such as endogenous metal-based drugs that include the copper-based compounds, casiopeinas [2]. On the other hand, casiopeinas are a family of more than 100 copper mixed-chelate coordination compounds with polypharmacological activities [3–6]. These compounds have been evaluated in cultures of murine tumor cell lines of melanoma, glioma, and leukemia. Additionally, they have shown activity in several human tumor cell cultures (colon, cervical, breast, lung, neuroblastoma, Lewis lung, and glioblastoma multiforme carcinoma) and presented efficacy in in vivo tests of xenograft tumor models with a colon carcinoma HCT-15 tumor [7–9]. CasIII-ia [Cu(4,4'-dimethyl-2,2'-bipyridine)(acetylacetonate)(NO3)] stands out amongst this group due to its solubility in water and lower toxicity than the more active analogs in preclinical studies [6]. Moreover, it exhibited a wide therapeutic range; thus, it was selected to start in a clinical phase I trial in Mexico [10,11]. Pharmacokinetic studies made
in Wistar rats and rabbits presented low drug blood concentration. Additionally, protein binding studies in human plasma proved that a decrease in CasIII-ia concentrations leads to an increase in protein binding [12,13]. The compiled background allowed us to propose the nanoencapsulation of CasIII-ia. In this sense, when CasIII-ia was loaded into chitosan nanoparticles [14], it was observed that CBF1/Hsd mice transplanted with B16 melanoma tumors had an increased life span compared to the animals which received the free drug. However, a high polydispersity particle size was obtained (150 nm–10 µm). Additionally, the encapsulation percentage was low due to the hydrophilicity of CasIII-ia [14].

Niosomes, like liposomes, are vesicular systems that can encapsulate both hydrophilic and lipophilic drugs. Niosomes are formed mainly by a nonionic surfactant that is less expensive than phospholipids and chemically stable; unlike phospholipids, surfactants do not require specific handling conditions [15]. One of the most widely used surfactants is Span 60° (S) since it allows a greater drug encapsulation efficiency [16,17]. Besides the surfactant, cholesterol (C) may increase the rigidity of the membrane, whereas Pluronic F127 (P) improves the physical stability of the vesicles [18,19].

Furthermore, the nanoformulation of metallodrugs represents one of the main challenges in the development of nanoparticles due to the metal’s capacity to react with the nanocarriers, which modifies the overall properties of the drug [1]. Therefore, the physicochemical and structural characteristics of the drug to be encapsulated must be considered. In addition, understanding the conditions and general factors involved in the final design of nanoparticles will allow modulating their physicochemical and biological properties [20,21]. To have consistency in those properties, the design, synthesis, manufacturing, and formulation of the pharmaceutical product must follow a systematic approach that uses quality-by-design (QbD) tools [22–24]. In the last five years, studies on the use of tools involved in quality by design (QbD) have been reported for platinum and vanadium [25,26].

Therefore, the present work proposes a nanoformulation consisting of niosomes bearing CasIII-ia designed and optimized with QbD tools for its IV administration. The advantages of the application of QbD in niosome formation and metal-based drug encapsulation is underlined.

2. Results
2.1. Quality-by-Design Approach
2.1.1. Risk Analysis (RA)

Among the quality target product profile (QTPP) elements, critical quality attributes (CQAs) and critical process parameters (CPPs), as well as the critical material attributes (CMAs) in the initial RA, were performed. The Ishikawa diagram (Figure 1) allowed the identification of all the potential factors of formulation and process parameters that influence the CQAs. The factors were collected and grouped into three sections (based on CPPs and CMAs, from the Ishikawa diagram), as they are related to the niosome formulation (drug and material properties), niosome preparation (ether injection method), and uncontrollable variables (relative humidity, room temperature, and residual solvent). After the identification of the risk with the Ishikawa diagram, a risk analysis was performed with RRMA, which is a qualitative tool for linking the likelihood of occurrence with the severity of harm to identify the impact of CMAs and CPPs on CQAs. Tables 1 and 2 present the estimated interrelationships of the selected critical factors for CMA and CPP factors. High risk represents risk that is not acceptable due to safety/efficacy issues; medium risk is acceptable but needs investigation; and low risk means no further investigation is needed [27]. The classification of the impact of each factor was realized based on previous reports, which allowed us to obtain knowledge of space development and identify the principal high-risk factors that may impact the formulation of metal-based drug encapsulation in niosomes. Then, variables were evaluated in experimental designs to find which had the greatest impact on the CQAs. The variables were divided into two categories: formulation and method of production. The variables obtained were as follows: CasIIIA concentration; S/C/P concentration; Pluronic F127 concentration; time during evaporation; speed during
evaporation; temperature injection; injection speed; speed during injection; and solvent volume.

Figure 1. Ishikawa diagram for CasIII-ia formulation in niosomes with critical material attributes and critical process parameters.

Table 1. Risk analysis based on critical material attributes.

| Drug                              | Additive (Pluronic F127) | Cholesterol Molar Ratio | Surfactant (Span 60) | Solvent | References                      |
|-----------------------------------|--------------------------|-------------------------|----------------------|---------|---------------------------------|
| CQAs                              |                          |                         |                      |         |                                 |
| Particle size                     | High                     | Low                     | Low                  | Medium  | High                            | [28–32] |
| Encapsulation efficiency          | High                     | High                    | Medium               | High    | Low                             | [15,16,30,33–36] |
| PDI                               | High                     | Low                     | Low                  | Medium  | High                            | [31] |
| Zeta potential                    | Medium                   | High                    | Low                  | Medium  | Low                             | [36–38] |

Table 2. Risk analysis based on critical parameter process.

| CQAs                              | Injection | Evaporation | Filtration | References |
|-----------------------------------|-----------|-------------|------------|------------|
| Particle size                     | High      | Low         | High       | [39–41]    |
| Encapsulation efficiency          | Medium    | Low         | Medium     | [39,41]    |
| PDI                               | High      | Low         | High       |            |
| Zeta potential                    | Medium    | Low         | Medium     |            |

2.1.2. Experimental Design

Once the risk analysis was performed and the main variables were defined, experimental designs were carried out to evaluate the effects of each factor on responses. The Plackett–Burman design was used to screen variables, whereas the factorial design and central composite design helped to predict and optimize the nanoformulation.
Plackett–Burman Design

Variables defined from the Plackett–Burman design (Table S1) were analyzed through Pareto charts of standardized effects, normalized tests, residue graphs, and ANOVAs. Variables are organized according to the effect: the highest effects appear beyond the red lines in the Pareto diagrams for particle size, PDI, surface charge, and encapsulation efficiency. Three main variables were selected according to their statistical significance ($p < 0.05$) and more frequent effect on the responses (observed in Pareto charts). Based on the results, drug concentration, niosome concentration, and the speed rate during injection were selected to be evaluated in a second design.

Factorial Design $2^k$

The optimization of the nanoformulation of a factorial design $2^3$ was executed. The three main variables obtained by the Plackett–Burman design were carried out in a two-level factorial design with three factors (Table S2). Pareto charts and variance analysis allowed us to identify which variables and interactions are statistically significant (Figure S1).

Variables and their interactions, on the CQAs, can be expressed quantitatively through a regression model. Then, linear regression equations were obtained for each response evaluated to obtain the best values of niosome formation from the desired values of CQAs. In general, for all cases (except for PDI), a good fit to the linear model was obtained where $R^2$ for each CQA was 97.35%, 75.15%, 97.77%, and 92.91% for particle size, PDI, EE, and surface charge, respectively. From the factorial design, central points can be added to evaluate whether a quadratic model might have a better fit for the data obtained from the experimental runs through a central composite design (CCD).

Central Composite Design

The CCD is obtained from an extension of the factorial design to which axial points are added to make the adjustment of the quadratic model possible with the linear variables, two-variable interaction, and quadratic terms of the continuous variables. The CCD helps to better understand and optimize the response. Eight experimental runs (two were central points and six were axial points) were added to the factorial design previously made. The twenty runs previously made (factorial design) and the new eight runs (CCD) performed were analyzed through Minitab 17 (Table S2). In the surface plot (Figure 2), the interactions between the variables are observed and those that are statistically significant were obtained by the analysis of variance, where it was observed that all factors influence particle size; however, for the other responses it was found that only the CasIII-ia concentration had a $p$-value $< 0.05$.

Quadratic equations helped to describe the individual main effect and the interaction effect of factors on the responses (CQAs). From the analysis of variance, residual, and normality plots (Figure S3) it was determined that the quadratic equations obtained are adequate for the prediction and optimization of the nanoformulation (Table S3). Based on the results, an optimization plot (Figure S2), obtained from the Minitab software, was used for identifying the combination of variable settings that jointly optimize the required values of CQAs (particle size of 150 nm and maximum encapsulation efficiency).
Figure 2. A 3D—response surface plot portraying the effect of the input variables on particle size, PDI, encapsulation efficiency, and surface charge.
2.2. Preparation of Optimized Nanoformulation

The validation of the applied QbD methodology was confirmed by selecting the operational conditions to prepare the optimized formulation of niosomes with CasIII-ia (Table 3).

Table 3. The niosome preparation conditions for optimized formulation (n = 3).

| Variables Conditions | CQAs Value          |
|----------------------|---------------------|
| 697 µM of S/C/P concentration | Maximum EE (40%) |
| 32 µM of CasIII-ia    | Particle size of 150 nm |
| 170 rpm of speed rate |                     |

Table 4 shows the results (predicted and observed values) obtained from the optimized conditions. It is possible to observe that the optimal conditions of particle size (150 nm) and encapsulation efficiency (40%) were obtained. Results show that experimental values are similar to predicted values.

Table 4. Particle size, EE, zeta potential, and PDI niosome with and without optimized CasIII-ia (n = 3).

| Particle Size (nm) | EE (%) | Zeta Potential (mV) | PDI     |
|--------------------|--------|---------------------|---------|
|                     | Observed | Predicted         | Observed | Predicted         |                     |
| Niosomes with CasIII-ia | 150.4 ± 4.66 | 150 ± 19.10 | 39.89 ± 4.99 | 40.44 ± 3.87 | −13.8 ± 1.25 | 0.234 ± 0.01 |
| Niosome blank      | 215 ± 1.92       | -              | -             | -               | −23.4 ± 1.95 | 0.231 ± 0.01 |

2.3. Optimized Nanoformulation Characterization

2.3.1. Electronic Microscopy

Spheric niosome morphology was observed with electronic microscopy. CasIII-ia inside the aqueous part of the vesicle is observed through the images obtained by STEM (without negative staining) (Figure 3a). In both TEM and STEM micrographs, the presence of the compound inside (TEM) and in the periphery (STEM) of the vesicles is indicated within the lighter areas due to the contrast generated by the copper atoms. Energy-dispersive spectroscopy (EDS) confirmed the presence of copper (Figure S4). In the micrographs obtained by TEM (with negative staining) (Figure 3b), bright regions (light) can be observed in the vesicles that could indicate that the uranyl acetate is immersed in the center of the vesicle (acoustical region), demonstrating that the vesiculation was carried out. Moreover, particle sizes around 150 nm were observed, which is consistent with the results observed by dynamic light scattering (Figure S5).

2.3.2. Thermal Analysis

From the optimized nanoformulation, DCS and TGA (Figure 4) were carried out for the niosome without CasIII-ia, niosome with CasIII-ia, and free CasIII-ia. In DSC, a small endothermic peak is observed for CasIII-ia around 85 °C due to the dehydration of CasIII-ia, and this was confirmed by TGA with the weight loss of the two water molecules. The DSC curve of niosomes without CasIII-ia shows a broad endothermic peak at 42 °C, which is due to conformational changes and the subsequent loss of crystallinity in the Span 60, cholesterol, and Pluronic F127 molecules during the vesiculation [42,43]. Incorporation of CasIII-ia in niosomes produced a displacement of the transition peak at 47 °C. The foregoing may be associated with the existence of CasIII-ia within the niosome, which could change the conformation of vesicles. The endothermic peak in niosomes at 105 °C is associated with the incorporation of Pluronin in the niosomal system. When the niosome does not contain Pluronin F127, this peak is not observed. Niosomes with CasIII-ia showed the highest intensity peak at 105 °C, which may be due to the interaction of CasIII-ia with
the niosome membrane. This supports the hypothesis that CasIII-ia molecules are found interacting with the niosomal membrane. An exothermic peak at 241 °C was observed in DSC for free CasIII-ia, corresponding to the degradation of the acetylacetonate ligand of CasIII-ia as reported elsewhere [14]. The latter was confirmed by TGA through weight loss. When the niosome with CasIII-ia was evaluated, the peak at 241 °C was not observed in either DSC or TGA. This behavior was also observed when the CasIII-ia was encapsulated in chitosan and was attributed to the incorporation of CasIII-ia inside the vesicle [14]. Moreover, the organic degradation (of niosome compounds) was observed at 380 °C in TGA.

![Image](a)

**Figure 3.** (a) STEM and (b) TEM images of the developed CasIII-ia niosomal formulation.

![Image](b)

**Figure 4.** (a) DSC and (b) TGA thermogram of CasIII-ia, niosome with and without CasIII-ia.

2.3.3. FTIR Studies

FTIR spectra (Figure 5) showed in the red line the characteristic bands of bipyridine and acetylacetonate of CasIII-ia (at 1616 cm\(^{-1}\), vibrations correspond to the C = N bond of bipyridine; at 1525 cm\(^{-1}\), vibrations C = C; at 1587 cm\(^{-1}\), corresponding to the carbonyl group of the acetylacetonate). On the other hand, in the niosome spectra, stretching
vibrations of the O-H bond (Span 60 and Pluronic F127) are observed at 3430 cm\(^{-1}\). Bands at 2920–2850 cm\(^{-1}\) are attributed to the C-H stretch vibrations of the saturated aliphatic group (Span 60 and Pluronic) and in the band at 1731 cm\(^{-1}\), the carbonyl stretches of the aliphatic ester functional group correspond to Span60. The band at 1384 cm\(^{-1}\) corresponds to the nitrate ion; this band appears in both spectra (CasIII-ia and niosome with CasIII-ia), whereas the characteristic bands of CasIII-ia are not observed in the niosome spectra with CasIII-ia, except nitrate ion, which is probably due to the encapsulation of the compound in concordance with the results obtained in the thermograms. However, through FTIR-ATR (Figure S6), it was observed that the characteristic bands of C = N in diimines in the CasIII-ia are present after the encapsulation of the compound, indicating a possible presence of the compound in the niosome membrane, which could explain the decrease in the zeta potential of the niosome when CasIII-ia is incorporated. Chitosan with CasIII-ia in FTIR studies does not show the characteristic bands of the drug inside the chitosan nanoparticle. This suggests that CasIII-ia can be loaded into chitosan nanoparticles [14].

![FTIR spectra](image)

**Figure 5.** FTIR spectra of CasIII-ia (red line), niosome blank (blue line), and niosome with CasIII-ia (black line).

2.3.4. Stability Studies

Accelerated stability studies (40 °C and 75% RH with \(n = 3\), according to NOM-073-SSA1-2015) were carried out for niosomes with and without CasIII-ia. The physical stability of the samples was evaluated by particle size, zeta potential, and polydispersity index (Figure 6). Following the results, after three months, for niosomes and niosomes with CasIII-ia, there was a decrease in particle size and zeta potential, and a decrease in the polydispersity index only for niosomes with CasIII-ia. The decrease in particle size was statistically significant only for Nio/CasIII-ia.
Figure 5. FTIR spectra of CasIII—ia (red line), niosome blank (blue line), and niosome with CasIII-ia (black line).

2.3.4. Stability Studies

Accelerated stability studies (40 °C and 75% RH with \( n = 3 \), according to NOM-073-SSA1-2015) were carried out for niosomes with and without CasIII-ia. The physical stability of the samples was evaluated by particle size, zeta potential, and polydispersity index (Figure 6). Following the results, after three months, for niosomes and niosomes with CasIII-ia, there was a decrease in particle size and zeta potential, and a decrease in the polydispersity index only for niosomes with CasIII-ia. The decrease in particle size was statistically significant only for Nio/CasIII-ia.

Figure 6. Accelerated stability studies (40 °C and 75% RH) for CasIII-ia in niosome-optimized formulation. The unpaired t-test was used to evaluate statistically significant groups (marked with an asterisk).

2.3.5. In Vitro Drug Release

The release profile of CasIII-ia (Figure 7) through the nanocarrier was biphasic with a fast release (burst effect) in the first hours, followed by a slower release for up to 33 h in accordance with a prolonged release. To evaluate the release profile of CasIII-ia from the niosome, the data obtained were fitted to zero-order, first-order, Higuchi model, and Korsmeyer–Peppas model kinetics (Table S4). The results indicated that the best fit was obtained with the Korsmeyer–Peppas model, meaning that the release of CasIII-ia is mainly governed by a Fick diffusion mechanism. The latter has been reported for drugs that are encapsulated in liposomes and niosomes [44,45].

Figure 7. Drug release profile of nanoencapsulated CasIII-ia (blue line) and profile of free CasIII-ia (red line) \((n = 3)\).

2.3.6. Cytotoxicity Assay

In vitro assays were performed on a triple-negative breast cancer tumor line (MDA-MB-231). Encapsulated CasIII-ia and the niosome blank were evaluated at different concentrations at 24 or 48 h after treatment, using the sulforhodamine B method [46]. Figure 8 shows a slight decrease in the activity of CasIII-ia as a product of encapsulation, compared to free CasIII-ia in both timeframes. However, encapsulated CasIII-ia reached 50% of
inhibition at a lower concentration when exposed to the cells for 48 h than for 24 h. In contrast, the niosome without CasIII-ia showed no activity at the concentrations and times evaluated.

![Figure 8](image_url)

**Figure 8.** Cytotoxic effect of MDA-MB-231 cell line treated with free CasIII-ia, CasIII-ia niosomal formulation, and niosome blank at different concentrations and times.

2.3.7. In Vivo Assays

In vivo study assays of CasIII-ia were performed in female BALB/c mice (*n* = 7). Cis-Pt was used as a control. Nonencapsulated CasIII-ia, nanoencapsulated CasIII-ia, and cis-Pt decreased the tumor growth speed (Figure 9a). Additionally, a decrease in the final weight of the primary tumor (Figure 9b) was observed, with all three treatments being statistically significant with respect to the untreated group.

![Figure 9](image_url)

**Figure 9.** (a) Tumor growth speed (TGS) was calculated from tumor size based on the difference between day 21 and day 1. The unpaired *t*-test was used to evaluate statistically significant groups (marked with an asterisk). (b) Primary tumor weight for each treatment group. The unpaired *t*-test was used to evaluate statistically significant groups (marked with an asterisk).

In addition, the weight of the mice was evaluated at the end of the treatment, where it was observed that only the groups treated with the niosome with CasIII-ia and niosome without CasIII-ia recovered their post-treatment weight. The effect was statistically significant with respect to the group treated with CasIII-ia. (Figure 10a), indicating lower
An unpaired t-test found that only the niosome-treated group was statistically significant concerning the untreated group. Despite the niosome with CasIII-ia being not statistically significant, this group shows a trend of lower toxicity.

Figure 10a shows there is less weight loss with the encapsulated CasIII-ia regarding the nonencapsulated CasIII-ia and cis-Pt. There was no significant difference between the niosome target and the 5% glucose solution, which could indicate low niosome activity.

3. Discussion

Nanocarriers can increase the rate to cross the gap for metallodrugs in clinical applications. The selection of carriers that are simple, easily scalable, approved, and compatible with the target metallodrugs will facilitate the clinical translation [1]. For the water-soluble compound CasIII-ia, a niosomal system with already approved and unreactive excipients (Span 60, cholesterol, and Pluronic F127) was used. The presence of the hydrophilic head and hydrophobic chain of Span 60 results in the formation of a double-layer structure that provides the host for hydrophilic and hydrophobic drugs. Niosomes are nanocarriers with a wide range of applications, an are mainly used in nanomedicine [47]. Niosomes contain a high number of variables for their formulation; therefore, strict control over variables of nanocarriers is required for optimizing the metallodrug formulation. In this sense, the use of quality-by-design tools allows for the optimization of metallodrug formulation through the definition of CQAs that impact QTPPs. For example, particle size and encapsulation efficiency (CQAs) are important factors for IV administration (QTPPs). In this sense, particle sizes between 100 and 200 nm are required, as they have been reported to show adequate fenestration through blood vessels [48,49]. High encapsulation efficiencies could decrease the binding of drugs to proteins. Consequently, the variables that impact the principal CQAs were evaluated in a screening design (Plackett–Burman). Subsequently, factorial and
central composite designs were utilized for formulation optimization. The experimental designs indicate that drug concentration is the key factor in the design of these niosomes. We observed that the particle size and encapsulation efficiency, principally, depend on the molecular weight of the compound to be nanoencapsulated, as reported by previous works [50]. S/C/P concentration and speed rate during injection have a lower impact on particle size and encapsulation efficiency. The behavior of the CQAs was modeled as a function of the three variables. A formulation with the operational conditions for a particle size of 150 nm and maximum encapsulation efficiency was realized. Experimental values are in accord with predicted values, indicating that the formulation is repeatable and reproducible. In addition, equations obtained may predict other formulations within the design space. For particle size, the predicted and experimental value was 150 nm. However, as was observed, the particle size increased when the niosomes were without CasIII-ia (215 nm); such an effect is the opposite of what has been reported for nanoencapsulated hydrophilic compounds. Usually, it is observed that when hydrophilic drugs are encapsulated, the particle size increases [51]. The decrease in particle size in the presence of CasIII-ia may be due to the presence of hydrogen bond interactions between the copper compound and the hydrophilic heads of Span 60 and Pluronic F127 chains; however, this hypothesis remains to be confirmed. Additionally, CasIII-ia molecules could be forming intermolecular interactions, leading to a decrease in particle size. CasIII-ia loaded into chitosan nanoparticles presents the same behavior, but has an encapsulation efficiency of 6% [14]. In this work, the efficiency encapsulation obtained of 40% may be due to the steric hindrance that could generate the chains of Pluronic F127 where the molecules are probably competing with the chains of the polymer and forming weak interactions with them. The latter would explain the obtained zeta potential of $-13.8$ mV compared to the zeta potential of $-23.4$ mV of the niosomes without CasIII-ia. Thus, we hypothesize that CasIII-ia may be on the surface of the vesicles, which diminishes the zeta potential. Computational methods such as DFT or particle dissipative dynamics would help to confirm the hypotheses of the interactions between drug molecules and those that make up the niosome; at the moment, this part is beyond the scope of this work. The intermolecular interaction and drug encapsulation had an influence on the modified drug delivery and the burst effect. Considering that 40% encapsulation was obtained, the burst effect could be due to the nonencapsulated CasIII-ia rapidly passing through the dialysis bag. Subsequently, a slower release of nonencapsulated CasIII-ia was found to form weak interactions with the niosome membrane. The longest release was a consequence of the encapsulated CasIII-ia. In contrast, almost 90% of the free-control CasIII-ia diffused out of the dialysis bag in the first hour of the study. The latter is characteristic of vesicular systems, such as liposomes and niosomes [52,53].

The increase in the in vitro activity of encapsulated CasIII-ia with respect to time can be correlated with the drug release tests where a modified release was observed. It indicates that the longer the time, the greater the complete delivery of the drug and, therefore, the greater the activity of the compound. Shaker and collaborators mention that the cytotoxic effect in MCF-7 cells (breast cancer) of tamoxifen loaded in niosomes is affected by the release time of the compound from the niosomal vesicles [33]. The nonactivity in the MDA-MB-231 tumor line of niosomes shown in in vitro assays is consistent with what was observed in in vivo studies. These results agree with Agarwal et al., who showed that niosomes have low activity in cancer cell lines and normal cells [54]. On the other hand, Haroun and collaborators observed lower toxicity (in breast cancer) in niosomes functionalized with PEG loaded with brucine (natural alkaloid) in comparison with free brucine [31]. They attributed this behavior to the enhanced and permeation retention effect, which increases the possibility of the niosomes reaching the site of action. In addition, the functionalization with PEG provides a longer circulation time of the niosomes [31]. The same behavior is observed with nanoparticles containing Pluronic F127 in the formulation.

In regard to the antitumor activity, cis-Pt and encapsulated and free-control CasIII-ia showed similar activities; however, cis-Pt showed the highest toxicity considering the
frequency of administration: every 7 days, four doses (cis-Pt) vs. every 4 days, six doses (encapsulated and free-control CasIII-ia).

The optimized and predicted formulation was obtained and characterized. The spheric shape of niosomes observed in TEM and STEM is characteristic of the vesicular system [52]. Results showed that the thickness of the membrane formed by the Span 60/cholesterol/Pluronic F127 is around 50 nm. This bilayer formation has also been observed by microscopy in other works [55].

Physical stability studies showed a decrease in zeta potential and in particle size. Copolymer Pluronic F127 is temperature-dependent. A rise in temperature at 40 °C could cause the dehydration of hydrophobic polypropylene oxide (PPO) blocks, causing the polymer chains to potentially come closer. The latter would cause the particle size and zeta potential to decrease in the blank niosome and niosome with CasIII-ia. A further decrease in the zeta potential in niosomes with CasIII-ia could be attributable to reaching an equilibrium between CasIII-ia and the niosome membrane. It has been observed that a negative zeta potential changes the value for niosomes with Pluronic L64 based on the temperature [56]. Although the particle size decreased and was statistically significant, the size is found to be between 100 and 150 nm, which is suitable for its use in intravenous administration [57]. Despite the decrease in the zeta potential, the decrease in particle size indicates there is no coalescence of the nanoparticles due to the steric hindrance caused by the long poly(propylene oxide) and poly(ethylene oxide) chains of Pluronic F127, which indicates physical stability for the niosomes with CasIII-ia for at least three months. These results agree with the reports made by other authors where niosomes are stable for at least 90 days [58,59].

4. Materials and Methods

4.1. Materials

Casiopeina® III-ia was synthesized at the National Autonomous University of Mexico. CAS [223930–33–4], the copper (II) complex was prepared following the reported patent [60]. Span 60® (S), cholesterol (C), and Pluronic F127® (P) were purchased from Sigma-Aldrich (Ciudad de México, Mexico). The analytical grade ethylic ether was purchased from Baker (Ciudad de México, Mexico). All reagents were used without further purification.

4.2. Methods

4.2.1. Quality-by-Design Approach: Risk Analysis

The Ishikawa diagram was constructed to identify all potential variables (formulation and formation method), which can have an impact on the CQAs (particle size, encapsulation efficiency, zeta potential, and polydispersity index) of the product, and therefore, alter the QTPPs. Later, a relative risk-based matrix analysis (RRMA) was performed based on a qualitative tool to identify the impact of an individual variable obtained from the Ishikawa diagram. The interdependence of the attribute of each CPP and CMA between CQAs was classified into high-, medium-, and low-risk attributes based on the impact on the finished product quality [27].

Quality Target Product Profile (QTPP)

QTPPs define the relationship between quality, security, and efficacy. Outlining the QTPP will define the CQAs, affecting the final product quality considerably. Table 5 describes the QTPP of nanoencapsulated CasIII-ia.

Critical Quality Attributes (CQAs)

The CQAs defined consider the IV administration, the physical and chemical characteristics of CasIII-ia, and the security of the product. CQAs are presented in Table 6.
Table 5. Quality target product profile for CasIII-ia nanoformulation.

| QTPP                      | Target                                              | Justification                                                                                                                                                                                                 |
|---------------------------|-----------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Dosage form               | Injectable solution                                 | Patent same dose form. Patent solicitude (MX/a/2017/016444) [61]. Casiopeinas have shown activity in tumor lines of cervical (HeLa, SiHa), breast (MCF-7), colon (HCT15), and neuroblastoma (CHP-212) cancers [9]. Moreover, CasIII-ia has shown tumor reduction in a nude mouse xenotransplanted (HCT-15) [62]. |
| Therapeutic indication    | Cancer treatment (phase I clinical trial of CasIII-ia)|                                                                                                                                                                                                             |
| Dosage design             | A modified-release dosage from a colloidal system  | Modified release to favor reaching the site of action of the compound by enhanced permeation and retention effect (EPR) [63–65]. Same route of administration as patent. Avoid the first-pass effect [61]. |
| Route of administration   | Intravenous                                         | In the solvent injection method, the use of sonication is not necessary for the reduction of particle size because it depends on experimental conditions and could be between 50 and 500 nm [28,35]. This represents a lower energy expenditure. Additionally, industrial scalability could result in better feasibility. |
| Production method         | Solvent ether injection; drug entrapment during niosome formation | Excipients are critical for niosome formation, entrapment efficiency, zeta potential, and blood circulation time [32,34,66].                                                                                                                                 |
| CQA excipients           | Span 60 (sorbitan monostearate), cholesterol and Pluronic F127 (poloxamer 407) | Measurement of particle size and PDI is related to the quality and safety profile of the preparation [48,67].                                                                                                                                                             |
| Stability                 | At least 6-month shelf-life at 40 °C and 75% RH; agrees with NOM-073-SSA1-2015 | To achieve the target shelf-life and to ensure quality during storage [61,68].                                                                                                                                                                                     |
| Container closure system  | Sterile glass vial                                  |                                                                                                                                                                                                             |

Table 6. Critical quality attributes for CasIII-ia nanoformulation.

| CQA                       | Target                                | Justification                                                                                                                                                                                                 |
|---------------------------|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Appearance                | Colorless liquid                      | Color and appearance are not important for quality.                                                                                                                                                           |
| Particle size             | 150 nm                                | Particles sizes between 20 and 50 nm present a high efficacy and safety. Sizes below 50 nm can suffer fenestration in organs such as the liver and fast-renal clearance. On the other hand, sizes above 200 nm could present spleen retention. Finally, sizes between 100 and 150 nm remain for a longer time in blood circulation [20,48]. The physical stability of vesicular systems depends on the total surface charge. Niosomes in solution require physical stability for storage and systemic circulation [21,48]. |
| Zeta potential            | ±30 mV                                | Niosomes with high PDI values modify the drug release profile, which may increase the toxicity of the drug.                                                                                                                                                                  |
| Polydispersity index (PDI)| Low                                   | Niosomes with high PDI values modify the drug release profile, which may increase the toxicity of the drug.                                                                                                                                                                  |
| Encapsulation efficiency  | Maximum                               | Encapsulation efficiency diminishes free casiopeina concentration and, consequently, its interaction with blood proteins. Residual solvents are an important toxic factor. Ether ethylic is a class 3 solvent, in agreement with ICH guideline Q3C. Class 3 solvents have low toxic potential [40]. Available data indicate they are less toxic in acute or short-time studies and negative in genotoxicity studies [40]. |
| Residual solvents         | Minimum                               |                                                                                                                                                                                                             |

Critical Process Parameters (CPPs) and Critical Material Attributes (CMAs)

CPPs and CMAs are variable parameters of the process that affect the CQAs and should be monitored or controlled for quality. CPPs and CMAs (from raw materials and
niosome formation) that could have a high impact on the CQA (particle size, EE, PDI, and superficial charge) were identified in the Ishikawa diagram.

4.2.2. Niosome Formation

Once the profile, parameters, and attributes were defined, the niosomes were prepared using a modified ether injection method [28,69] described as follows: Span 60 and cholesterol (1:1 molar, [70,71]) were dissolved in ethyl ether. Pluronic F127 and CasIII-ia were dissolved in distilled water. The ether dissolution was added into a volume of CasIII-ia/Pluronic F127 solution water drop by drop using a syringe pump (kdScientific Model 100 series) on a magnetic stirrer. Then, the organic solvent was removed by a slow magnetic stirrer at room temperature for one hour. The suspension was filtered through a syringe filter (Merck MillexTM, PES 0.22 µm). A blank of niosome was prepared in the same way. The conditions for Plackett–Burman and factorial design niosome formation are presented in Tables S1 and S2. For total Span 60/Cholesterol/Pluronic F17 (S/C/P) concentrations: Pluronic F127 was used in a range of 2.5–5% molar; cholesterol and Span 60 in a range of 47.5–48.5% molar each.

4.2.3. Quality-by-Design Approach: Experimental Design (DoE)

Once the procedure of the niosome formation was recognized, Plackett–Burman and factorial designs were used to screen the variables and optimize the nanoformulation. Experimental designs were created and analyzed with Minitab 17 statistical software (State College, PA, USA). For all experimental designs, the niosomes were prepared according to Section 4.2.2.

Plackett–Burman Design

Nine variables were selected through the Ishikawa diagram. The variables were screened through a Plackett–Burman design to identify the most important factors that affect the CQAs. The factors evaluated were: time of evaporation (A), speed rate during evaporation (B), temperature of injection (C), injection rate (D), speed rate during injection (E), solvent volume (F), CasIII-ia concentration (G), S/C/P concentration (H), and P concentration (I). The responses evaluated were particle size (Y₁), polydispersity index (Y₂), superficial charge (Y₃), and encapsulation efficiency (Y₄). Each factor was evaluated at low (−1) and high (+1) levels and three central points (0) were added to detect curvature. ANOVA analysis and Pareto charts were used to demonstrate the influence of each factor on the response. The results are shown in Table S1.

Factorial Design 2ᵏ

Based on the screening study results, the three main effects obtained (S/C/P concentration, drug concentration, and speed rate during injection) were carried out in a two-level factorial design with three factors. The variables that were not statistically significant or did not have a major impact on the evaluated effects were fixed at some value, according to the description depicted in Table 7.

The factorial design considered tests of power and sample size. In total, 20 experimental runs were carried out divided into 4 blocks, with 2 replicates each and 4 central points, with a base design of 3.8. The twenty runs were made and analyzed using Minitab 17 (Table S2).

Central Composite Design (CCD)

The CCD was obtained from an extension of the factorial design to which axial points, called star points, points were added to obtain the response surface plot. To improve the statistical power, eight experimental runs (two central and six axial points) were added to the factorial design previously made. The CCD optimizes the response and allows a better understanding of the system and its variables. A mapping of each variable was performed.
and, depending on the surface response, it was possible to select the optimal configuration for each factor. The new eight runs (CCD) were analyzed through Minitab 17 (Table S2).

Table 7. Conditions for niosome formation in factorial design $^2$.

| Evaporation | Time | Speed rate | Estimated time for ethyllic ether evaporation |
|-------------|------|------------|---------------------------------------------|
| Temperature | 50 °C | 50 rpm | Phase-transition temperature (Tc) of Span 60 is 60 °C. However, cholesterol can reduce phase-transition temperature (Tc) $^{[32]}$. |
| Injection | 40 mL/h | Variable | Chiraz et al. reported that the injection rate has no significant effect on the mean vesicle size $^{[72]}$. |
| Solvent volume | 2.5 mL | Variable | Smaller solvent volumes can increase particle size due to fast evaporation. Higher volumes imply higher residual solvent. |
| Formulation | CasIII-ia concentration | Variable | A 2.5–5% additive concentration is recommended. Higher concentrations inhibit niosome formation $^{[73]}$. |
| | S/C/P concentration | Variable | |
| | P concentration | 3% | |

4.2.4. Optimized Formulation: Niosome Characterizations

After the risk analysis and experimental design, the optimized formulation was characterized by several techniques to determine the morphological and physical characteristics, particle size, drug encapsulation, drug release, and in vivo and in vitro activity.

Particle Size and Polydispersity Index (PDI)

To establish the particle size and determine the polydispersity index, dynamic light scattering (DLS) was performed. For particle size, PDI, and zeta potential, a Zetasizer Nano Zen 3600 with scattering angle of 173°; water viscosity of 0.8872; and refractive index of 1.496 at 25 °C and zeta dip cell were used, respectively. Three independent samples from each sample were measured at room temperature. The niosomal dispersion was not diluted.

Superficial Charge

The electrokinetic surface was determined by means of particle charge. It was measured with a Mutek PCD 03 particle charge detector. A sample of niosomes was diluted with deionized water (2.5 mL sample/7.5 mL water).

Encapsulation Efficiency (EE)

Encapsulation efficiency allows for the quantification of the encapsulated drug. Briefly, a sample was centrifuged at 12,150 × g at 4 °C for one hour. The amount of unencapsulated CasIII-ia in the supernatant was measured spectrophotometrically (UV–visible diode array spectrophotometer 8452A) at λ= 294 nm. For each batch, a blank of niosomes was prepared with the same concentration of niosomes, but without the CasIII-ia. A calibration curve (range 8 × 10–6 M–8 × 10–4 M) was constructed for the quantification of the percentage of encapsulation. The encapsulation efficiency was calculated according to the following equation:

$$EE = \frac{\text{amount of encapsulated CasIII-ia}}{\text{total amount of CasIII-ia used for the preparation of niosome}} \times 100 \quad (1)$$

Electronic Microscopy

Niosome morphology was analyzed by transmission electron microscopy (JOEL JEM-2010) for negative staining and by scanning transmission electron microscopy (Bruker Nano GmbH D-12498). One drop of the sample was placed on a carbon continued-film nickel
grid and it was dried at room temperature. Finally, one drop of uranyl acetate 1% \( w/v \) was placed on the same grid.

Fourier Transform Infrared Spectroscopy (FTIR) and Attenuated Total Reflectance Infrared Spectroscopy (ATR-FTIR)

FTIR and ATR-FTIR were performed to verify the encapsulation of CasIII-ia. The obtained niosomes/CasIII-ia, blank niosomes, and free CasIII-ia were characterized with the classical pellet KBr method by FTIR (Nicolet Avatar 320, Thermo Scientific). Spectral transmittance over the spectral range from 4000 to 400 cm\(^{-1} \) was evaluated.

For ATR-FTIR, a lyophilized sample (niosomes/CasIII-ia, blank niosomes, and free CasIII-ia) was evaluated in the Nicolet iS5 with an iD5 ATR accessory from Thermo Scientific. Spectral transmittance over the spectral range from 4000 to 500 cm\(^{-1} \) was evaluated.

Thermal Analysis

Differential calorimetry scanning (DSC) and thermogravimetry analysis (TGA) were used to characterize the thermal behavior of niosomes and niosomes with CasIII-ia. For the DSC study (DSC/700 Mettler Toledo), a sample of 2 mg of lyophilized powder was crimped in a standard aluminum pan and heated from 20 to 300 \(^{\circ} \)C at a heating constant rate of 10 \(^{\circ} \)C/min. For the TGA study (TGA 4000 System, PerkinElmer, 100–240 V/50–60 Hz), a sample of 10 mg was weighed and heated from 10 to 550 \(^{\circ} \)C at a heating constant rate of 10 \(^{\circ} \)C/min under a nitrogen atmosphere.

4.2.5. Physical Stability Study

To establish the physical stability of the niosomes, the optimized formulation obtained (CasIII-ia or blank niosome) was placed in a 3 mL glass vial. Each container \( (n = three) \) was placed in a temperature and humidity chamber, MAYASA model CEHT 12000, at 40 \(^{\circ} \)C and 75% HR. The particle size, zeta potential, and polydispersity index were determined at zero and three months. The procedure was carried out as described in the Mexican Standard NOM-073-SSA1-2015.

4.2.6. In Vitro Drug Release

In vitro drug release was evaluated with the dialysis bag method. A regenerated cellulose dialysis bag of 12–14 KDa (Spectrum Labs, Asheville, NC, USA) was hydrated and washed with water for half an hour. The dialysis bag was suspended in a 40 mL PBS and shook at 37 ± 0.5 \(^{\circ} \)C at 160 \( \times \) g. A sample of 0.5 mL of the prepared niosomal with CasIII-ia dispersions was placed in the donor compartment. Then, samples were taken at fixed times for 35 h; the sample taken from the receiver compartment was replenished with the same volume. A sample of blank niosomes and a free CasIII-ia sample were evaluated under the same methodology. The drug release was assayed by spectrophotometry at 294 nm and the data were adjusted to zero-order, first-order, Higuchi and Korsmeyer–Peppas model.

4.2.7. In Vitro Cell Assays

In vitro cytotoxicity experiments were performed to evaluate the effect of the CasIII-ia nanoformulations on hormonal-independent triple-negative breast cancer (MDA-MB-231). The process was carried out. Briefly, cells were harvested and cultivated in 96-well plates with 2 \( \times \) 104 cells each and 100 \( \mu \)L of the medium. The plates were incubated at 37 \(^{\circ} \)C and in a 5% CO\(_2\) atmosphere. The next day, the medium was withdrawn and 100 \( \mu \)L of dissolutions containing niosomes, niosomes without CasIII-ia, or free CasIII-ia niosomes (range of 1–106 \( \mu \)M) were added. Cell cultures were exposed for 24 h or 48 h of treatment. Finally, the medium was retired, and plates were fixed and stained with sulforhodamine B to assess cell viability according to the procedure described by Skehan [46].
4.2.8. In Vivo Test

The in vivo evaluation was realized using 36 5-week-old BALB/c female mice, donated by the FES Zaragoza animal house. Following the approved protocol of FEZ-CE/22-118-08, mice were implanted with 10,000 cells (4T1, metastatic breast cancer model) contained in 100 µL of serum-free RPMI that was subcutaneously injected near the mammary pad (4th pair). After the appearance of the tumor (about 10 days after implantation), treatments were administered intraperitoneally (ip). The 30 animals were divided into 5 groups, distributed as followed: (A) control; (B) glucose solution 5% (SG); niosome/SG (1.45 mg/kg) 4 doses every 4 days; CasIII-ia (6 mg/kg) 6 doses every 4 days; cis-Pt (4 mg/kg) 4 doses every 7 days; niosome/CasIII-ia (1.45 mg/kg/6 mg/kg) 6 doses every 4 days. At the end of treatment, the animals were weighed and the tumor was measured in length and width. The percentage of weight loss and toxicity was calculated for each animal.

5. Conclusions

The QbD tool was used for the development of the niosome/CasIII-ia with the potential for IV administration. The QTPP was defined and used as a guide for pharmaceutical development. The Ishikawa diagram and RRMA analysis were made from the selection of materials and methods for niosome formation, and the CQAs, CPPs, CMAs, and experimental designs were defined according to ICH standards of QbD for prediction and optimization of a formulation. The first experimental design was carried out (Plackett–Burman, variable screening), where it was found that the main variables to consider were drug concentration, niosome concentration, and agitation speed during the injection. These variables were evaluated in a factorial $2^3$ design. It was found that the model presented a curvature, which is the reason why the design was adjusted to a central compound design, as it was possible to optimize the formulation of CasIII-ia with the niosomal systems. Drug concentration was the most important variable for niosome formulation. The operational conditions were 697 µM of S/C/P, 32 µM of CasIII-ia, and a 170 rpm speed rate. The obtained particle size and encapsulation efficiency were predicted according to the optimization graphs, at 150 nm and 40%, respectively; the particle size was less polydisperse and there was an improved encapsulation efficiency with respect to the chitosan nanoparticle. Thermogravimetric (TGA and DSC) and spectroscopic (FTIR) studies were carried out to confirm the incorporation of the compound inside the system. The microscopy studies showed that the niosomes are spheres with homogeneous sizes. Niosomes with and without CasIII-ia are physically stable for at least 3 months under accelerated conditions. A biphasic diffusion-governed release of CasIII-ia was observed, and this modified release coincides with the results obtained in the MDA-MB-231 cell line, where a higher activity of encapsulated CasIII-ia was observed at 48 h of study, giving a better distribution of the drugs that provide a better therapeutic effect. In the in vivo studies, also, it was observed that encapsulated CasIII-ia shows lower toxicity concerning cis-Pt and nonencapsulated CasIII-ia. A reduction in toxicity could allow a higher dose to be administered to improve effectiveness. This work opens up a window of opportunity for the formulation of coordination compounds in niosomes using quality tools that allow optimization. The optimal conditions obtained through QbD may improve the scaling-up process.

Supplementary Materials: The supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms232112756/s1.

Author Contributions: Conceptualization, L.R.-A. and Z.A.-J.; methodology, Z.A.-J.; validation, A.E.-G., M.G.-B. and Z.A.-J.; formal analysis, Z.A.-J.; investigation, Z.A.-J. and M.G.-B.; resources, L.R.-A.; writing—original draft preparation, Z.A.-J.; writing—review and editing, Z.A.-J., L.R.-A. and S.G.D.-M.; supervision, L.R.-A.; funding acquisition, L.R.-A. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by UNAM-PAIP 5000-9047 and CONACyT 314819. Zenayda Aguilar-Jiménez was supported by grants for doctoral studies from CONACyT Scholarship 335903.
Institutional Review Board Statement: A total of 36 healthy female (6–8 weeks old) BALB/c mouse strains were kept in the animal facilities at FES-Zaragoza, UNAM, under controlled conditions, including a temperature of 22 °C; a relative humidity of 50–60%; and 12 h dark–light cycle, with lights on between 7:00 a.m. and 9:00 p.m. The mice had free access to food and water ad libitum. All animals were handled in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and the national regulations for the care and use of experimental animals (NOM-062-ZOO-1999). All experimental protocols were approved by the Ethics Committee of FES-Zaragoza FEZ-CE/22-118-08.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: We would like to acknowledge David Díaz and Josefa Bernad-Bernad from UNAM for allowing the use of their laboratories for dynamic light scattering and the in vitro drug release study; Miguel Ángel-Méndez from UDLAP for STEM micrography; USAII-UNAM for TEM micrography and thermic analysis; José Aguilar-Jiménez for providing language help; Karen Reséndiz-Acevedo for their support in cytotoxicity studies; Luis Sánchez from FES Zaragoza and Miguel Zavala from UAM Xochimilco for their support in the in vivo tests; UAM Xochimilco UPEAL-biotherium for providing the female BALB/c mice; and Laura Padierna and Karyna Pérez-Saldaña from the Laboratorios de Especialidades Inmunológicas S.A. de C.V for their generous donation of chemicals and culture media.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Peña, Q.; Wang, A.; Zaremba, O.; Shi, Y.; Scheeren, H.W.; Metelsaar, J.M.; Kiessling, F.; Pallares, R.M.; Wuttke, S.; Lammers, T. Metallodrugs in Cancer Nanomedicine. Chem. Soc. Rev. 2022, 51, 2544–2582. [CrossRef] [PubMed]
2. Allardyce, C.S.; Dyson, P.J. Metal-Based Drugs That Break the Rules. Dalton Trans. 2016, 45, 3201–3209. [CrossRef] [PubMed]
3. Proschak, E.; Stark, H.; Merk, D. Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds. J. Med. Chem. 2019, 62, 420–444. [CrossRef] [PubMed]
4. Barbosa, A.R.; Caleffi-Ferracioli, K.R.; Leite, C.Q.F.; García-Ramos, J.C.; Toledano-Magaña, Y.; Ruiz-Azuara, L.; Siqueira, V.L.D.; Pavan, F.R.; Cardoso, R.F. Potential of Casiopeínas® Copper Complexes and Antituberculosis Drug Combination against Mycobacterium Tuberculosis. Chemotherapy 2016, 61, 249–255. [CrossRef]
5. Rufino-González, Y.; Ponce-Macotela, M.; García-Ramos, J.C.; Martínez-Gordillo, M.N.; Galindo-Murillo, R.; González-Maciél, A.; Reynoso-Robles, R.; Tovar-Tovar, A.; Flores-Alamo, M.; Toledano-Magaña, Y.; et al. Antigliadastic Activity of Cu(II) Coordination Compounds: Redox Imbalance and Membrane Damage after a Short Exposure Time. J. Inorg. Biochem. 2019, 195, 83–90. [CrossRef]
6. Bravo-gómez, M.E.; García-ramos, J.C.; Gracia-mora, I.; Ruiz-azuara, L. Antiproliferative Activity and QSAR Study of Copper (II) Mixed Chelate [Cu(N-N)(acetylacetonato)] NO3 and [Cu(N-N)(glycinato)NO3] Complexes. J. Inorg. Biochem. 2019, 103, 299–309. [CrossRef]
7. Castillo-Rodriguez, R.A.; Palencia, G.; Anaya-Rubio, I.; Gallardo-Pérez, J.C.; Jiménez-Farfán, D.; Escamilla-Ramírez, Á.; Zavala-Vega, S.; Cruz-Salgado, A.; Cervantes-Rebolledo, C.; Gracia-Mora, I.; et al. Anti-Proliferative, pro-Apoptotic and Anti-Invasive Effect of the Copper Coordination Compound Cas III-La through the Induction of Reactive Oxygen Species and Regulation of Wnt/β-Catenin Pathway in Glioma. J. Cancer 2021, 12, 5693–5711. [CrossRef]
8. Resendiz-Acevedo, K.; García-Aguillera, M.E.; Esturau-Escofet, N.; Ruiz-Azuara, L. 1H-NMR Metabolomics Study of the Effect of Cisplatin and Casiopeina Ilgly on MDA-MB-231 Breast Tumor Cells. Front. Mol. Biosci. 2021, 8, 742859. [CrossRef]
9. González-Ballesteros, M.M.; Mejía, C.; Ruiz-Azuara, L. Metallodrugs: An Approach against Invasion and Metastasis in Cancer Treatment. FEBS Open Bio. 2022, 12, 880–899. [CrossRef]
10. Leal-García, M.; García-Ortuño, L.; Ruiz-Azuara, L.; Gracia-Mora, I.; Luna-Delvillar, J.; Sumano, H. Assessment of Acute Respiratory and Cardiovascular Toxicity of Casiopeinas in Anaesthetized Dogs. Basic Clin. Pharmacol. Toxicol. 2007, 101, 151–158. [CrossRef]
11. Serment-Guerrero, J.; Cano-Sanchez, P.; Reyes-Perez, E.; Velazquez-Garcia, F.; Bravo-Gomez, M.E.; Ruiz-Azuara, L. Genotoxicity of the Copper Antineoplastic Coordination Complexes Casiopeinas®. Toxicol. Vitr. 2011, 25, 1376–1384. [CrossRef] [PubMed]
12. Correia, I.; Borovic, S.; Cavaco, I.; Matos, C.P.; Roy, S.; Santos, H.M.; Fernandes, L.; Capelo, J.L.; Ruiz-Azuara, L.; Pessoa, J.C. Evaluation of the Binding of Four Anti-Tumor Casiopeinas® to Human Serum Albumin. J. Inorg. Biochem. 2017, 175, 284–297. [CrossRef] [PubMed]
13. Cañas-Alonso, R.C.; Fuentes-Noriega, I.; Ruiz-Azuara, L. Pharmacokinetics of Casiopeina Ilgly in Beagle Dog: A Copper Based Compound with Antineoplastic Activity. J. Bioanal. Biomed. 2010, 2, 28–34. [CrossRef]
14. Miranda-Calderón, J.E.; Macías-Rosales, L.; Gracia-Mora, I.; Ruiz-Azuara, L.; Faustino-Vega, A.; Gracia-Mora, J.; Bernad-Bernad, M.J. Effect of Casiopine III-La Loaded into Chitosan Nanoparticles on Tumor Growth Inhibition. *J. Drug Deliv. Sci. Technol.* 2018, 48, 1–8. [CrossRef]

15. Masjedi, M.; Montahaei, T. An Illustrated Review on Nonionic Surfactant Vesicles (Niosomes) as an Approach in Modern Drug Delivery: Fabrication, Characterization, Pharmaceutical, and Cosmetic Applications. *J. Drug Deliv. Sci. Technol.* 2021, 61, 102234. [CrossRef]

16. Sankhyan, A.; Pawar, P.K. Metformin Loaded Non-Ionic Surfactant Vesicles: Optimization of Formulation, Effect of Process Variables and Characterization. *Durr J. Fac. Pharm.* 2013, 21, 7. [CrossRef]

17. Nasr, M.; Mansour, S.; Mortada, N.D. Elshamy, a Vesicular Aceclofenac Systems: A Comparative Study between Liposomes and Niosomes. *J. Microencapsul.* 2008, 25, 499–512. [CrossRef]

18. Sakai, T.; Kurosawa, H.; Okada, T.; Mishima, S. Vesicle Formation in Mixture of a PEO-PPO-PEO Block Copolymer (Pluronic P123) and a Nonionic Surfactant (Span 65) in Water. *Colloids. Surfaces A Physicochem. Eng. Asp.* 2011, 389, 82–89. [CrossRef]

19. Manosroi, A.; Wongtrakul, P.; Manosroi, J.; Sakai, H.; Sugawara, F.; Yuasa, M.; Abe, M. Characterization of Vesicles Prepared with Various Non-Ionic Surfactants Mixed with Cholesterol. *Colloids Surfaces B Biointerfaces* 2003, 30, 129–138. [CrossRef]

20. Stylianopoulos, T.; Jain, R.K. Design Considerations for Nanotherapeutics in Oncology. *Nanomedicine* 2015, 11, 1893–1907. [CrossRef]

21. Beddoes, C.M.; Case, C.P.; Briscoe, W.H. Understanding Nanoparticle Cellular Entry: A Physicochemical Perspective. *Adv. Colloid. Interface Sci.* 2015, 218, 48–68. [CrossRef] [PubMed]

22. Rawal, M.; Singh, A.; Amiji, M.M. Quality-by-Design Concepts to Improve Nanotechnology-Based Drug Development. *Pharm. Res.* 2019, 36, 153. [CrossRef] [PubMed]

23. Bastogne, T. Quality-by-Design of Nanopharmaceuticals—A State of the Art. *Nanomedicine* 2017, 13, 2151–2157. [CrossRef] [PubMed]

24. European Medicines Agency (EMA) Committee for Human Medicinal Products. *ICH Guideline Q8 (R2) on Pharmaceutical Development;* European Medicines Agency: Amsterdam, The Netherlands, 2017.

25. Cacicedo, M.L.; Ruiz, M.C.; Scioli-Montoto, S.; Ruiz, M.E.; Fernández, M.A.; Torres-Sanchez, R.M.; Baran, E.J.; Castro, G.R.; León, I.E. Lipid Nanoparticles-Metvan: Revealing a Novel Way to Deliver a Vanadium Compound to Bone Cancer Cells. *New J. Chem.* 2019, 43, 17726–17734. [CrossRef]

26. Patel, V.; Bardoliwala, D.; Lalani, R.; Patil, S.; Ghosh, S.; Javia, A.; Misra, A. Development of a Dry Powder for Inhalation of Nanoparticles Codelivering Cisplatin and ABCG2 SiRNA in Lung Cancer. *Ther. Deliv.* 2021, 12, 651–670. [CrossRef]

27. Waghule, T.; Dabholkar, N.; Gorantla, S.; Rapalli, V.K.; Saha, R.N.; Singhvi, G. Quality by Design (QbD) in the Formulation and Delivery: Fabrication, Characterization, Pharmaceutical, and Cosmetic Applications. *J. Drug Deliv. Sci. Technol.* 2021, 70, 103322. [CrossRef]

28. Moghassemi, S.; Hadjizadeh, A. Nano-Niosomes as Nanoscale Drug Delivery Systems: An Illustrated Review. *J. Control. Release* 2014, 185, 22–36. [CrossRef]

29. Waddad, A.Y.; Abbad, S.; Yu, F.; Munyendo, W.L.L.; Wang, J.; Lv, H.; Zhou, J. Formulation, Characterization and Pharmacokinetics of Morin Hydrate Niosomes Prepared from Various Non-Ionic Surfactants. *Int. J. Pharm.* 2013, 456, 446–458. [CrossRef]

30. Hao, Y.M.; Li, K. Entrapment and Release Difference Resulting from Hydrogen Bonding Interactions in Niosome. *Adv. Colloid. Interface Sci.* 2015, 218, 48–68. [CrossRef] [PubMed]

31. Haroun, M.; Elsewedy, H.S.; Shehata, T.M.; Tratratt, C.; Al Dhubiab, B.E.; Venugopala, K.N.; Almostafa, M.M.; Kochkar, H.; Elnahas, H.M. Significant of Injectable Brucine PEGylated Niosomes in Treatment of MDA Cancer Cells. *Daru J. Fac. Pharm.* 2015, 23, 493, 285–294. [CrossRef]

32. Chen, S.; Hanning, S.; Falconer, J.; Locke, M.; Wen, J. Recent Advances in Non-Ionic Surfactant Vesicles (Niosomes): Fabrication, Characterization, Pharmaceutical and Cosmetic Applications. *Eur. J. Pharm. Biopharm.* 2019, 144, 18–39. [CrossRef] [PubMed]

33. Shaker, D.S.; Shaker, M.A.; Hanafy, M.S. Cellular Uptake, Cytotoxicity and in-Vivo Evaluation of Tamoxifen CitrateLoaded Niosomes. *Int. J. Pharm.* 2015, 493, 285–294. [CrossRef] [PubMed]

34. Mohamed, H.B.; El-Shanawany, S.M.; Hamad, M.A.; Elsabahy, M. Niosomes: A Strategy toward Prevention of Clinically Significant Drug Incompatibilities. *Sci. Rep.* 2017, 7, 6340. [CrossRef] [PubMed]

35. Rajera, R.; Nagpal, K.; Singh, S.K.; Mishra, D.N. Niosomes: A Controlled and Novel Drug Delivery System. *Biol. Pharm. Bull.* 2011, 34, 945–953. [CrossRef]

36. Yang, H.; Deng, A.; Zhang, J.; Wang, J.; Lu, B. Preparation, Characterization and Anticancer Therapeutic Efficacy of Cisplatin-Loaded Niosomes. *J. Microencapsul.* 2013, 30, 237–244. [CrossRef]

37. Sharma, V.; Anandhakumar, S.; Sasidharan, M. Self-Degrading Niosomes for Encapsulation of Hydrophilic and Hydrophobic Drugs: An Efficient Carrier for Cancer Multi-Drug Delivery. *Mater. Sci. Eng. C* 2015, 56, 393–400. [CrossRef]

38. Sezgin-Bayindir, Z.; Antep, M.N.; Yuksel, N. Development and Characterization of Mixed Niosomes for Oral Delivery Using Candesartan Cilexetil as a Model Poorly Water-Soluble Drug. *AAPS PharmSciTech.* 2015, 16, 108–117. [CrossRef]

39. Duong, V.A.; Nguyen, T.T.L.; Maeng, H.J. Preparation of Solid Lipid Nanoparticles and Nanostructured Lipid Carriers for Drug Delivery and the Effects of Preparation Parameters of Solvent Injection Method. *Molecules* 2020, 25, 4781. [CrossRef]

40. European Medicines Agency ICH Guideline Q3C (R6) on Impurities: Guideline for Residual Solvents. *Int. Conf. Harmon. Tech. Requir. Regist. Pharm. Hum. Use* 2019, 31, 24.
69. Baillie, A.J.; Florence, A.T.; Hume, L.R.; Muirhead, G.T.; Rogerson, A. The Preparation and Properties of Niosomes—Non-ionic Surfactant Vesicles. *J. Pharm. Pharmacol.* **1985**, *37*, 863–868. [CrossRef]

70. Sabry, S.; El hakim Ramadan, A.; Abd elghany, M.; Okda, T.; Hasan, A. Formulation, Characterization, and Evaluation of the Anti-Tumor Activity of Nanosized Galangin Loaded Niosomes on Chemically Induced Hepatocellular Carcinoma in Rats. *J. Drug Deliv. Sci. Technol.* **2021**, *61*, 102163. [CrossRef]

71. Uchegbu, I.F.; Vyas, S.P. Non-Ionic Surfactant Based Vesicles (Niosomes) in Drug Delivery. *Int. J. Pharm.* **1998**, *172*, 33–70. [CrossRef]

72. Jaafar-Maalej, C.; Diab, R.; Andrieu, V.; Elaissari, A.; Fessi, H. Ethanol Injection Method for Hydrophilic and Lipophilic Drug-Loaded Liposome Preparation. *J. Liposome Res.* **2010**, *20*, 228–243. [CrossRef]

73. Marianecci, C.; Rinaldi, F.; Carafa, M.; Marianecci, C.; Di, L.; Rinaldi, F.; Celia, C.; Paolino, D.; Alhaigne, F.; Esposito, S.; et al. Niosomes from 80s to Present: The State of the Art. *Adv. Colloid. Interface Sci.* **2013**, *205*, 187–206. [CrossRef]